Oncology Based Molecular Diagnostics Market Demand, Analysis and Future Scope 2034
Oncology Based Molecular Diagnostics Market Growth, Size, Trends Analysis- By Type, By Product, By Technology - Regional Outlook, Competitive Strategies and Segment Forecast to 2034
| Published: Jul-2025 | Report ID: BIOT2502 | Pages: 1 - 210 | Formats*: |
| Category : Biotechnology | |||
Oncology Based Molecular Diagnostics Market Introduction and Overview
According to SPER Market Research, the Global Oncology Based Molecular Diagnostics Market is estimated to reach USD 12.47 billion by 2034 with a CAGR of 12.36%.
The report includes an in-depth analysis of the Global Oncology Based Molecular Diagnostics Market, including market size and trends, product mix, Applications, and supplier analysis.The global molecular oncology diagnostics market is projected to grow significantly due to the rising incidence of cancers like breast, colorectal, and Non-Small Cell Lung Cancer (NSCLC), alongside advances in biomarker identification and diagnostic technologies. Increased awareness among patients and healthcare professionals about early cancer detection is driving the adoption of molecular tests. Innovations in tumor modeling, computational analysis, and research methods further support this trend. For example, Illumina launched a pan-cancer companion diagnostic in May 2022 for its TruSight Oncology Comprehensive (EU) test, helping match rare genetic mutations with targeted therapies. Meanwhile, unhealthy lifestyle habits—such as poor diet, physical inactivity, smoking, alcohol use, and obesity—continue to fuel cancer cases, especially in low- and middle-income countries with limited healthcare infrastructure.
By Type:
This segment primarily focuses on cancers such as breast, prostate, colorectal, cervical, liver, lung, blood, and kidney cancers. Among these, breast cancer holds a leading position in market share, driven by high testing volumes and a wide range of available products. Liver, prostate, and colorectal cancer diagnostics are also expected to grow significantly due to rising prevalence and greater public awareness. Molecular oncology diagnostics continue to evolve, supporting personalized medicine and driving advancements in diagnostic technology and drug discovery.
By Technology:
The polymerase chain reaction (PCR) segment leads the market, driven by its increasing use in research laboratories and the growing demand for advanced diagnostic solutions. The industry is categorized into several key technologies, including PCR, In Situ Hybridization, Isothermal Nucleic Acid Amplification, Chips & Microarrays, Mass Spectrometry, Sequencing, and Transcription Mediated Amplification. Among these, sequencing is expected to grow rapidly, supported by rising investments in research and its expanding role in clinical diagnostics due to faster processing and efficient turnaround times.
By Product:
The reagents segment dominates the market, largely due to their extensive use in cancer diagnostics and testing. Growth in molecular biology and advancements in biotechnology, along with increasing demand for synthetic biology and rising R&D investments by biotech firms, are key drivers of this segment's rapid expansion. Additionally, innovations continue to emerge, such as Agilent Technologies’ CE-IVD marked PD-L1 IHC 22C3 pharmDx assay, introduced for esophageal cancer patients to help identify those likely to benefit from KEYTRUDA treatment.
Regional Insights:
North America leads the market, driven by its advanced healthcare infrastructure, growing health-conscious population, and substantial healthcare spending. Meanwhile, the Asia Pacific region is projected to experience the fastest growth in the coming years. This surge is largely due to a rising incidence of tumors in low- and middle-income countries, linked to aging populations and lifestyle shifts stemming from economic development and epidemiological changes. Countries such as India, China, and Australia are expected to present significant opportunities for market expansion, supported by improving economies and a high level of unmet medical needs.
Market Competitive Landscape:
The global Oncology Based Molecular Diagnostics Market is highly consolidated. Some of the market key players are Abbott, Bayer AG, BD, Cepheid, Agilent Technologies, Inc., Danaher, Hologic, Inc., Qiagen, F. Hoffmann-La Roche Ltd., Siemens.
Recent Developments:
- In November 2023, Abbott received U.S. FDA approval for its molecular human papillomavirus (HPV) screening test within the Alinity m series of in-vitro diagnostics. This approval enabled the company to expand its product portfolio, contributing to increased sales and revenue growth.
- In June 2022, Agilent announced the acquisition of Resolution Bioscience, aiming to enhance its precision medicine portfolio by strengthening its next-generation sequencing (NGS)-based cancer diagnostic capabilities. This move highlighted Agilent's commitment to expanding its footprint in the liquid biopsy market and advancing its expertise in developing in vitro diagnostic tests.
Scope of the report:
| Report Metric | Details |
| Market size available for years | 2021-2034 |
| Base year considered | 2024 |
| Forecast period | 2025-2034 |
| Segments covered | By Type, By Product, By Technology |
| Regions covered | North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa |
| Companies Covered | Abbott, Bayer AG, BD, Cepheid, Agilent Technologies, Inc., Danaher, Hologic, Inc., Qiagen, F. Hoffmann-La Roche Ltd., Siemens. |
Key Topics Covered in the Report
- Global Oncology Based Molecular Diagnostics Market Size (FY’2021-FY’2034)
- Overview of Global Oncology Based Molecular Diagnostics Market
- Segmentation of Global Oncology Based Molecular Diagnostics Market By Type (Breast Cancer, Prostate Cancer, Colorectal Cancer, Cervical Cancer, Liver Cancer, Lung Cancer, Blood Cancer, Kidney Cancer, Other Cancer)
- Segmentation of Global Oncology Based Molecular Diagnostics Market By Product (Instruments, Reagents, Others)
- Segmentation of Global Oncology Based Molecular Diagnostics Market By Technology (PCR, In Situ Hybridization, INAAT, Chips and Microarrays, Mass Spectrometry, Sequencing, TMA, Others)
- Statistical Snap of Global Oncology Based Molecular Diagnostics Market
- Expansion Analysis of Global Oncology Based Molecular Diagnostics Market
- Problems and Obstacles in Global Oncology Based Molecular Diagnostics Market
- Competitive Landscape in the Global Oncology Based Molecular Diagnostics Market
- Details on Current Investment in Global Oncology Based Molecular Diagnostics Market
- Competitive Analysis of Global Oncology Based Molecular Diagnostics Market
- Prominent Players in the Global Oncology Based Molecular Diagnostics Market
- SWOT Analysis of Global Oncology Based Molecular Diagnostics Market
- Global Oncology Based Molecular Diagnostics Market Future Outlook and Projections (FY’2025-FY’2034)
- Recommendations from Analyst
1. Introduction
- 1.1. Scope of the report
- 1.2. Market segment analysis
2. Research Methodology
- 2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPERs internal database
- 2.1.4. Premium insight from KOLs
- 2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
- 2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
- 4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges
5. Market variable and outlook
- 5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
- 5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
- 5.3. PORTERs Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
- 5.4. Heat Map Analysis
6. Competitive Landscape
- 6.1. Global Oncology Based Molecular Diagnostics Market Manufacturing Base Distribution, Sales Area, Product Type
- 6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Oncology Based Molecular Diagnostics Market
7. Global Oncology Based Molecular Diagnostics Market, By Type, (USD Million) 2021-2034
- 7.1. Breast Cancer
- 7.2. Prostate Cancer
- 7.3. Colorectal Cancer
- 7.4. Cervical Cancer
- 7.5. Liver Cancer
- 7.6. Lung Cancer
- 7.7. Blood Cancer
- 7.8. Kidney Cancer
- 7.9. Other Cancer
8. Global Oncology Based Molecular Diagnostics Market, By Product, (USD Million) 2021-2034
- 8.1. Instruments
- 8.2. Reagents
- 8.3. Others
9. Global Oncology Based Molecular Diagnostics Market, By Technology, (USD Million) 2021-2034
- 9.1. PCR
- 9.2. In Situ Hybridization
- 9.3. INAAT
- 9.4. Chips and Microarrays
- 9.5. Mass Spectrometry
- 9.6. Sequencing
- 9.7. TMA
- 9.8. Others
10. Global Oncology Based Molecular Diagnostics Market, (USD Million) 2021-2034
- 10.1. Global Oncology Based Molecular Diagnostics Market Size and Market Share
11. Global Oncology Based Molecular Diagnostics Market, By Region, 2021-2034 (USD Million)
- 11.1. Asia-Pacific
- 11.1.1. Australia
- 11.1.2. China
- 11.1.3. India
- 11.1.4. Japan
- 11.1.5. South Korea
- 11.1.6. Rest of Asia-Pacific
- 11.2. Europe
- 11.2.1. France
- 11.2.2. Germany
- 11.2.3. Italy
- 11.2.4. Spain
- 11.2.5. United Kingdom
- 11.2.6. Rest of Europe
- 11.3. Middle East and Africa
- 11.3.1. Kingdom of Saudi Arabia
- 11.3.2. United Arab Emirates
- 11.3.3. Qatar
- 11.3.4. South Africa
- 11.3.5. Egypt
- 11.3.6. Morocco
- 11.3.7. Nigeria
- 11.3.8. Rest of Middle-East and Africa
- 11.4. North America
- 11.4.1. Canada
- 11.4.2. Mexico
- 11.4.3. United States
- 11.5. Latin America
- 11.5.1. Argentina
- 11.5.2. Brazil
- 11.5.3. Rest of Latin America
12. Company Profile
- 12.1. Abbott
- 12.1.1. Company details
- 12.1.2. Financial outlook
- 12.1.3. Product summary
- 12.1.4. Recent developments
- 12.2. Bayer AG
- 12.2.1. Company details
- 12.2.2. Financial outlook
- 12.2.3. Product summary
- 12.2.4. Recent developments
- 12.3. BD
- 12.3.1. Company details
- 12.3.2. Financial outlook
- 12.3.3. Product summary
- 12.3.4. Recent developments
- 12.4. Cepheid
- 12.4.1. Company details
- 12.4.2. Financial outlook
- 12.4.3. Product summary
- 12.4.4. Recent developments
- 12.5. Agilent Technologies, Inc.
- 12.5.1. Company details
- 12.5.2. Financial outlook
- 12.5.3. Product summary
- 12.5.4. Recent developments
- 12.6. Danaher
- 12.6.1. Company details
- 12.6.2. Financial outlook
- 12.6.3. Product summary
- 12.6.4. Recent developments
- 12.7. Hologic, Inc.
- 12.7.1. Company details
- 12.7.2. Financial outlook
- 12.7.3. Product summary
- 12.7.4. Recent developments
- 12.8. Qiagen
- 12.8.1. Company details
- 12.8.2. Financial outlook
- 12.8.3. Product summary
- 12.8.4. Recent developments
- 12.9. F. Hoffmann-La Roche Ltd.
- 12.9.1. Company details
- 12.9.2. Financial outlook
- 12.9.3. Product summary
- 12.9.4. Recent developments
- 12.10. Siemens
- 12.10.1. Company details
- 12.10.2. Financial outlook
- 12.10.3. Product summary
- 12.10.4. Recent developments
- 12.11. Others
13. Conclusion
14. List of Abbreviations
15. Reference Links
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
Frequently Asked Questions About This Report
Oncology Based Molecular Diagnostics Market is projected to reach USD 39.4 billion by 2034, growing at a CAGR of 12.36% during the forecast period.
Oncology Based Molecular Diagnostics Market grew in Market size from 2025. The Market is expected to reach USD 39.4 billion by 2034, at a CAGR of 12.36% during the forecast period.
Oncology Based Molecular Diagnostics Market CAGR of 12.36% during the forecast period.
You can get the sample pages by clicking the link - Click Here
Oncology Based Molecular Diagnostics Market size is USD 39.4 billion from 2025 to 2034.
Oncology Based Molecular Diagnostics Market is covered By Type, By Product, By Technology
The North America is anticipated to have the highest Market share in the Oncology Based Molecular Diagnostics Market.
Abbott, Bayer AG, BD, Cepheid, Agilent Technologies, Inc., Danaher, Hologic, Inc., Qiagen, F. Hoffmann-La Roche Ltd., Siemens.
The report includes an in-depth analysis of the Global Oncology Based Molecular Diagnostics Market, including market size and trends, product mix, Applications, and supplier analysis
PLACE AN ORDER
Year End Discount
Sample Report
Pre-Purchase Inquiry
NEED CUSTOMIZATION?
Request CustomizationCALL OR EMAIL US
100% Secure Payment
Related Reports
Have a glance of the Report
Our Global Clients
Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
